EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Chronicling the Journey of Pneumococcal Conjugate Vaccine Introduction in India

Pawan Kumar, Arindam Ray iD, Amrita Kumari iD, Abida Sultana, Rhythm Hora iD, Kapil Singh iD, Rashmi Mehra, Amanjot Kaur iD, Seema Singh Koshal iD, Syed F Quadri, Shyam Kumar Singh iD, Arup Deb Roy iD

Vaccines · 21.04.2025 · 13 (4) · 432

DOI: 10.3390/vaccines13040432 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 21.04.2025. Verfasst von Pawan Kumar und 11 weiteren Autor:innen. Beteiligte Einrichtung: Immunization Division, Ministry of Health & Family Welfare, Government of India, New Delhi 110011, India. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill & Melinda Gates Foundation, Gates Foundation, Bill & Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Globally, pneumonia claims the lives of about 700,000 children under the age of 5 every year. Pneumococcal conjugate vaccine (PCV) was introduced in India phase-wise, beginning in high-burden states, and the rollout was completed nationwide by 2021—representing a major initiative by the Ministry of Health and Family Welfare (MoHFW). Despite the challenges posed by the COVID-19 pandemic, the campaign succeeded in maintaining progress and achieving nationwide coverage. This narrative review highlights the significant decisions, processes, and coordinated efforts of the various stakeholders involved that led to this successful PCV rollout. Methodology: A comprehensive desk review of both published and unpublished literature relevant to pneumonia burden and the efficacy and effectiveness of PCVs, along with documentation of PCV introduction and the scale-up was carried out.

Results

The documentation of the PCV journey has been broken down into four sections: pre-introduction, PCV Phase-I introduction, pan-India rapid expansion, and the period post-introduction. Since the nationwide rollout in 2021, PCV coverage in India has steadily increased, reflecting successful immunization efforts. WUENIC, which is an annual WHO, and UNICEF estimates of national immunization coverage also show a positive trend in vaccination coverage (PCV booster coverage = 25% (2021), rising to 83% (2023), aligning with the goals of the WHO and UNICEF’s Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD).

Conclusions

The phased rollout was an ambitious effort by the MoHFW, which was particularly challenging given the overlap with the COVID-19 pandemic. Despite these hurdles, the MoHFW, along with strong collaboration from development partners and stakeholders, successfully navigated the complex rollout. Future studies on the role of PCVs in reducing antibiotic resistance and the economic benefits of PCV introduction could help policymakers sustain funding and prioritize vaccine procurement decisions.

Schlagwörter

Stichwörter der Autor:innen

COVID-19pneumococcal conjugate vaccineuniversal immunization program

Autor:innen und Institutionen

  • Immunization Division, Ministry of Health & Family Welfare, Government of India, New Delhi 110011, India.
  • Gates Foundation, New Delhi 110067, India.
  • John Snow India, New Delhi 110070, India.

ORCID-Profile: Arindam Ray, Amrita Kumari, Rhythm Hora, Kapil Singh, Amanjot Kaur, Seema Singh Koshal, Shyam Kumar Singh, Arup Deb Roy

Förderung

  • Bill & Melinda Gates Foundation
  • Gates Foundation
  • Bill & Melinda Gates Foundation

Zitieren

APA

Kumar, P., Ray, A., Kumari, A., Sultana, A., Hora, R., Singh, K., Mehra, R., Kaur, A., Koshal, S. S., Quadri, S. F., Singh, S. K., & Roy, A. D. (2025). Chronicling the Journey of Pneumococcal Conjugate Vaccine Introduction in India. Vaccines, 13(4), 432. https://doi.org/10.3390/vaccines13040432

Vancouver

Kumar P, Ray A, Kumari A, Sultana A, Hora R, Singh K, et al. Chronicling the Journey of Pneumococcal Conjugate Vaccine Introduction in India. Vaccines. 2025;13(4):432. doi:10.3390/vaccines13040432

BibTeX
@article{Kumar2025,
  author = {Kumar, Pawan and Ray, Arindam and Kumari, Amrita and Sultana, Abida and Hora, Rhythm and Singh, Kapil and Mehra, Rashmi and Kaur, Amanjot and Koshal, Seema Singh and Quadri, Syed F and Singh, Shyam Kumar and Roy, Arup Deb},
  title = {Chronicling the Journey of Pneumococcal Conjugate Vaccine Introduction in India},
  journal = {Vaccines},
  year = {2025},
  volume = {13},
  number = {4},
  pages = {432},
  doi = {10.3390/vaccines13040432}
}
Kostenlos starten →